ClinicalTrials.gg
CompletedNCT00659100Updated Feb 2, 2021

A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment

A Phase 3 interventional study of Gabapentin in Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,254
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.

Enrollment
2nd of 14
1,254 · median 283
Started
2006
with 1 other
Phase 3
9 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
9 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one is the 2nd largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 2nd registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders as a file.
02

Study summary

The purpose of this study is to assess consumers' behaviors related to gabapentin self- selection and use, relative to warnings and directions for use, as described in the proposed over-the-counter (OTC) product label.

03

Conditions studied

  • Transient Insomnia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 years or older with symptoms of sleeplessness
  • Provided

Exclusion criteria

Exclusion Criteria:

  • to use of gabapentin
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,254 participants (actual)

Study arms

  • Experimental
    A

    Drug: Gabapentin

Interventions

  • Gabapentin 50 mg oral capsule 30 minutes before bedtime

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who selected or purchased gabapentin for use (patients had symptoms consistent with indication and no contraindications)

    Time frame: Throughout Day 90

  2. Subject compliance with directions for use (number of capsules per dose and the number of doses per day)

    Time frame: Throughout Day 90

Secondary outcomes

  1. Adverse events

    Time frame: Duration of study

07

Study locations

35 sites
  • Pfizer Investigational Site
    Anaheim, California 92801, United States
  • Pfizer Investigational Site
    Bonita, California 91902, United States
  • Pfizer Investigational Site
    Fallbrook, California 92028, United States
  • Pfizer Investigational Site
    Hacienda Heights, California 91746, United States
  • Pfizer Investigational Site
    La Mesa, California 91942, United States
  • Pfizer Investigational Site
    Oceanside, California 92054, United States
  • Pfizer Investigational Site
    Orange, California 92866, United States
  • Pfizer Investigational Site
    San Dimas, California 91773, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33026, United States
  • Pfizer Investigational Site
    Weston, Florida 33326, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21228, United States
  • Pfizer Investigational Site
    Elk River, Minnesota 55330, United States
  • Pfizer Investigational Site
    Northfield, Minnesota 55057, United States
  • Pfizer Investigational Site
    Red Wing, Minnesota 55066, United States
  • Pfizer Investigational Site
    Saint Louis Park, Minnesota 55426, United States
  • Pfizer Investigational Site
    Holly Springs, Mississippi 38625, United States
  • Pfizer Investigational Site
    Belton, Missouri 64012, United States
  • Pfizer Investigational Site
    Independence, Missouri 64054, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87104, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87110, United States
  • Pfizer Investigational Site
    Taos, New Mexico 87571, United States
  • Pfizer Investigational Site
    Cary, North Carolina 27513, United States
  • Pfizer Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27606, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27609, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27612, United States
  • Pfizer Investigational Site
    Houston, Texas 77088, United States
  • Pfizer Investigational Site
    Pearland, Texas 77581, United States
  • Pfizer Investigational Site
    Bountiful, Utah 84010, United States
  • Pfizer Investigational Site
    Ogden, Utah 84401, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84121, United States
  • Pfizer Investigational Site
    Syracuse, Utah 84075, United States
  • Pfizer Investigational Site
    West Valley City, Utah 84120, United States
  • Pfizer Investigational Site
    Falls Church, Virginia 22041, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23233, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 16, 2008
Start
Aug 2006
CompletionActual
Jan 2007
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00659100
Responsible party
Sponsor
First posted
Apr 16, 2008
Start date
Aug 2006
Completion
Jan 2007
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion